Naunyn-Schmiedeberg's
Naunyn-Schmiedeberg's Arch. Pharmacol. 297, S 99 - S 101 (1977)
Archivesof Pharmacology 9 by SpringerWerlag 1977
Participation of Prostaglandins in Pathogenesis of Aspirin-Sensitive Asthma ANDRZEJ
SZCZEKLIK, RYSZARD
J. G R Y G L E W S K I ,
and G R A Z Y N A
CZERNIAWSKA-MYSIK
Departments of Allergy and Clinical Immunology, and Pharmacology, Copernicus Academy of Medicine, 31-066 Cracow, 8 Skawinska, Poland SUMMARY:
Recent evidence
suggests that the
induction of bronchoconstriction
in as-
pirin-sensitive patients by analgesics
of
oral challenge tests in which 13 different is
due to the inhibiton of PG biosynthesis their respiratory tract.
This statement is based on the results
in
PGEs might play
non-steroidal anti-inflammatory
drugs were
administered to 90 patients with aspirinsensitive asthma
(Szczeklik et al., 1975;
the main defensive role in the bronchi of
Szczeklik et al., 1976). The results re-
aspirin-sensitive
vealed that in addition to indomethacin
asthmatics.
Removal of
this potent bronchodilator by PG syntheta-
and mefenamic acid, which were already re-
se inhibitors
ported by other authors,
leaves the effects of spas-
mogens unopposed,
and possibly promotes
the release of histamine
from its stores.
several non-stero-
idal anti-inflammatory With different chemical structure)drugs were able to induce bronchospasm in aspirin-sensitive
KEY W O R D S :
asthma,
Prostaglandins,
bronchial
tics. These included:
aspirin
fen,
ibuprofen,
phenylbutazone. Among patients with bronchial asthma there is a group which can be distinguished clinical grounds rate aspirin.
since they do not tole-
In these patients
asthmaticattacks
on
severe
diclofenac,
asthmafenopro-
napro•
All these drugs markedly
inhibited prostaglandin biosynthesis microsomes
and
in
of bovine seminal vesicles,
rabbit kidney and rabbit brain. 2. Drugs which did not in hibit PG synthe-
occur within minutes to
hours following ingestion os aspirin.
flufenamate,
This
type of asthma has been estimated as va-
tase in vitro
(IC50~ 1.000 ~M) did not in-
duce any change in lung function of the aspirin-sensitive patients.
The drugs were
rying from 4 to 20 per cent among adult following: asthmatics.
The pathogenesis
of this
disorder has remained unknown.
salicyl~de,
benzydamine, chloro-
quine and dextropropo~phene.
In few aspirin-
Allergic sensitive patients these drugs were admi-
mechanism has been excluded by extensive immunological studies.
We propose that in
the sensitive patients
induction of asthma-
nistered over a period of a week in a dose of 5 tablets a day without any untoward reaction.
tic attacks by aspirin-like drugs is due 3. There is a good correlation between the to inhibition of prostaglandin biosyntheability of the drugs to induce bronchoconsis. The evidence can be summarized as follows:
striction in the sensitive patients and the inhibitory potency on prostaglandin
i. Only the drugs which inhibit prostaglandin biosynthesis
synthesis in vivo
(Szczeklik et al., 1975;
Szczeklik et al.,
1976). Thus,
in vitro induce bronchothe stron-
constriction in the sensitive patients. gest inhibitor,
indomethacin,
was also the
S 100 most powerful bronchoconstrictor in the
the ~-adrenergic one. Such a concept is in
clinical setting.
agreement with clinical observations sug-
phenylbutazone,
On the other hand,
as expected,
showed the
gesting that the importance of various me-
lowest degree of the activity in the
diators is not the same ~in different types
patients.
of asthma
4. Each aspirin-sensitive patient is cha-
Removal of endogenous PGE by PG syntheta-
racterized by an individual pattern of
se inhibitors deprives the respiratory
sensitivity
tract of a potent bronchodilator,
(Szczeklik et al., 1976).
(Szczeklik et al., to be published).
and
Thus, patients sensitive to low doses of
leaves the effects of endogenous broncho-
aspirin also respond to low doses of in-
constrictor unopposed.
domethacin,
of PGE might promote the histamine release.
fenoprofen and ibuprofen, while
Furthermore,
lack
those who develop obstruction to airflow
In vitro, PGEs stabilize membranes of ma-
only following relatively high doses of
stocytes, inhibit their degranulation,
aspirin also need high doses of other
and block the release of histamine
drugs to respond with bronchoconstriction.
tenstein,
These results can be explained by ~hhibi-
fore, opens the way to histamine action,
tion o~ the bronchial prostaglandin syn-
to which patients with aspirin-induced
thetase. They also indicate that the degree
asthma are highly sensitive
of enzymic inhibition which is sufficient
al., to be published).
to precipitate bronchoconstriction
be of clinical importance.
is an
individual hallmark of each patient.
(Lich-
1973). Removal of PGE, there-
(Szczeklik et
This mechanism may Arroyave et al.
(1976) reported that a significant rise
5. The enzymic system generating PGE in
in plasma histamine occurs in aspirin-
nasal polyp pieces of aspirin-sensitive
sensitive asthmatics following aspirin
patients has an increased susceptibility
oral challenge.
to the inhibitory action of aspirin
remained unchanged in aspirin-non-sensi-
(Szczeklik et al., to be published).
Plasma histamine levels
These
tive asthmatics and healthy subjects. We
observations appear relevant to the patho-
observed that the obstruction of airflow
genesis of the disorder discussed,
since
following aspirin ingestion can b e s i g n i -
chronic nasal congestion and
ficantly attenuated in sensitive patients
rhinorrhea,
nasal polyps are among the prominent
by the pretreatment with disodium cromo-
symptoms of the development of aspirin-
glycate.
sensitivity in the asthmatics.
of 240 mg on two consecutive days pre-
The in-
This drug inhaled in a daily dose
creased susceptibility to inhibitory a~ion
ceeding the aspirin challenge and admi-
of aspirin appears not to be restricted
nistered additionally i m m e d i a t e l y b e f o r e
to
nasal mucosa, but may also occur in
the challenge, protected completely 3 sen-
other parts of the respiratory tract,.
sitive patients against aspirin-induced
namely in bronchi.
bronchoconstriction and markedly diminished
The question which
remains to be answered is: Why does the
the bronchospastic reaction in 3 others.
inhibition of PG biosynthesis bring
Disodium cromoglycate has no bronchodila-
bronchoconstriction?
about
Our general concept
is that PGEs along with the
~ad:renergic
system play the main defensive role in
ting properties, but inhibits the release of histamine and possibly of other spasmogens from mastocytes.
These results indi-
bronchial asthma. However, aspirin-sen~
cate that several secondary mechanism may
sitive patients differ from other asthma-
be involved in the final pathway leading
tics as well as from healthy subjects by
to bronchial obturation in the sensitive
relying more on the PGEs mechanism than on
patients. We believe, however, that the results point to PGs as the modulators of
S 101
primary importance in pathogenesis of aspirin-sensitive asthma. ACKNOWLEDGEMENT This study was supported by NIH Special Foreign Currency Agreement USA N ~ 05-082 N, and by Wellcome Trust. REFERENCES Arroyave, C.M., Stevenson, D.D., Bhatt, K.N., Tan, E.M.: Oral challenge in asthmatic patients: a study of plasma mediators (abstr.) J. Allergy Clin. Immunol. 57, 206 (1976) Lichtenstein, L.M.: The control of IgE-mediated histamine release, in: Asthma, eds. by K.F. Austen and L.M. Lichtenstein, Academic Press, New York-London, 1973, p. 91 Szczeklik, A., Gryglewski, R.J., Czerniawska-Mysik, G.: Relationship of inhibition of prostaglandin biosynthesis by analgesics to asghma attacks in aspirin-sensitive patients. Br. Med. J. &, 67-69 (1975). Szczeklik, A., Gryglewski, R.J., Czerniawska-Mysik, G., Zmuda, A.: Aspirininduced asthma: Hypersensitivity to Fenoprofen and Ibuprofen in relation to their inhibitory action on prostaglandin generation by different microsomal preparations. J. Allergy Clin. Immunol. 58, 10-18 (1976)